Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil
Abstract
:1. Introduction
2. Materials, Methods, and Results
3. Discussion
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Watanabe, T.; Kiso, M.; Fukuyama, S.; Nakajima, N.; Imai, M.; Yamada, S.; Murakami, S.; Yamayoshi, S.; Iwatsuki-Horimoto, K.; Sakoda, Y.; et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature 2013, 501, 551–555. [Google Scholar] [CrossRef] [PubMed]
- Imai, M.; Watanabe, T.; Kiso, M.; Nakajima, N.; Yamayoshi, S.; Iwatsuki-Horimoto, K.; Hatta, M.; Yamada, S.; Ito, M.; Sakai-Tagawa, Y.; et al. A Highly Pathogenic Avian H7N9 Influenza Virus Isolated from A Human Is Lethal in Some Ferrets Infected via Respiratory Droplets. Cell host & microbe. 2017, 22, 615–626 e618. [Google Scholar] [CrossRef]
- Hayden, F.G.; Sugaya, N.; Hirotsu, N.; Lee, N.; de Jong, M.D.; Hurt, A.C.; Ishida, T.; Sekino, H.; Yamada, K.; Portsmouth, S.; et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N. Engl. J. Med. 2018, 379, 913–923. [Google Scholar] [CrossRef] [PubMed]
- Omoto, S.; Speranzini, V.; Hashimoto, T.; Noshi, T.; Yamaguchi, H.; Kawai, M.; Kawaguchi, K.; Uehara, T.; Shishido, T.; Naito, A.; et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep. 2018, 8, 9633. [Google Scholar] [CrossRef] [PubMed]
- Takashita, E.; Kawakami, C.; Morita, H.; Ogawa, R.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018. Euro. Surveill. 2019, 24. [Google Scholar] [CrossRef] [PubMed]
- Takashita, E.; Kawakami, C.; Ogawa, R.; Morita, H.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Euro. Surveill. 2019, 24. [Google Scholar] [CrossRef] [PubMed]
- Takashita, E.; Ichikawa, M.; Morita, H.; Ogawa, R.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019. Emerg. Infect. Dis. 2019, 25, 2108–2111. [Google Scholar] [CrossRef] [PubMed]
- Gao, R.; Cao, B.; Hu, Y.; Feng, Z.; Wang, D.; Hu, W.; Chen, J.; Jie, Z.; Qiu, H.; Xu, K.; et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 2013, 368, 1888–1897. [Google Scholar] [CrossRef] [PubMed]
- Mok, C.K.; Lee, H.H.; Lestra, M.; Nicholls, J.M.; Chan, M.C.; Sia, S.F.; Zhu, H.; Poon, L.L.; Guan, Y.; Peiris, J.S. Amino acid substitutions in polymerase basic protein 2 gene contribute to the pathogenicity of the novel A/H7N9 influenza virus in mammalian hosts. J. Virol. 2014, 88, 3568–3576. [Google Scholar] [CrossRef] [PubMed]
- Yamayoshi, S.; Yamada, S.; Fukuyama, S.; Murakami, S.; Zhao, D.; Uraki, R.; Watanabe, T.; Tomita, Y.; Macken, C.; Neumann, G.; et al. Virulence-affecting amino acid changes in the PA protein of H7N9 influenza A viruses. J. Virol. 2014, 88, 3127–3134. [Google Scholar] [CrossRef]
- Yamayoshi, S.; Fukuyama, S.; Yamada, S.; Zhao, D.; Murakami, S.; Uraki, R.; Watanabe, T.; Tomita, Y.; Neumann, G.; Kawaoka, Y. Amino acids substitutions in the PB2 protein of H7N9 influenza A viruses are important for virulence in mammalian hosts. Sci. Rep. 2015, 5, 8039. [Google Scholar] [CrossRef]
- Yamayoshi, S.; Kiso, M.; Yasuhara, A.; Ito, M.; Shu, Y.; Kawaoka, Y. Enhanced Replication of Highly Pathogenic Influenza A(H7N9) Virus in Humans. Emerg. Infect. Dis. 2018, 24, 746–750. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Qi, W.; Qiao, J.; Chen, C.; Liao, M.; Xiao, C. Evolving HA and PB2 genes of influenza A (H7N9) viruses in the fifth wave - Increasing threat to both birds and humans? J. Infect. 2017, 75, 184–186. [Google Scholar] [CrossRef]
- Zhang, F.; Bi, Y.; Wang, J.; Wong, G.; Shi, W.; Hu, F.; Yang, Y.; Yang, L.; Deng, X.; Jiang, S.; et al. Human infections with recently-emerging highly pathogenic H7N9 avian influenza virus in China. J. Infect. 2017, 75, 71–75. [Google Scholar] [CrossRef]
- Monthly Risk Assessment Summary. Available online: https://www.who.int/influenza/human_animal_interface/HAI_Risk_Assessment/en/. (accessed on 6 October 2019).
- Zeng, X.; Tian, G.; Shi, J.; Deng, G.; Li, C.; Chen, H. Vaccination of poultry successfully eliminated human infection with H7N9 virus in China. Sci. China Life Sci. 2018, 61, 1465–1473. [Google Scholar] [CrossRef] [PubMed]
- Yu, D.; Xiang, G.; Zhu, W.; Lei, X.; Li, B.; Meng, Y.; Yang, L.; Jiao, H.; Li, X.; Huang, W.; et al. The re-emergence of highly pathogenic avian influenza H7N9 viruses in humans in mainland China, 2019. Euro. Surveill. 2019, 24. [Google Scholar] [CrossRef] [PubMed]
- Taniguchi, K.; Ando, Y.; Nobori, H.; Toba, S.; Noshi, T.; Kobayashi, M.; Kawai, M.; Yoshida, R.; Sato, A.; Shishido, T.; et al. Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Sci. Rep. 2019, 9, 3466. [Google Scholar] [CrossRef] [PubMed]
- Zumla, A.; Memish, Z.A.; Maeurer, M.; Bates, M.; Mwaba, P.; Al-Tawfiq, J.A.; Denning, D.W.; Hayden, F.G.; Hui, D.S. Emerging novel and antimicrobial-resistant respiratory tract infections: New drug development and therapeutic options. Lancet Infect. Dis. 2014, 14, 1136–1149. [Google Scholar] [CrossRef]
Group No. | Compound | Concentration | Treatment Regimen a |
---|---|---|---|
1 | Methylcellulose | 0.5% | – |
2 | Oseltamivir phosphate | 5 mg/kg | Twice a day for 5 days |
3 | Oseltamivir phosphate | 50 mg/kg | Twice a day for 5 days |
4 | Baloxavir marboxil | 1.5 mg/kg | Once, 1 h post-virus inoculation |
5 | Baloxavir marboxil | 15 mg/kg | Once, 1 h post-virus inoculation |
6 | Baloxavir marboxil | 50 mg/kg | Once, 1 h post-virus inoculation |
7 | Baloxavir marboxil | 1.5 mg/kg | Twice a day for 5 days |
8 | Baloxavir marboxil | 15 mg/kg | Twice a day for 5 days |
9 | Baloxavir marboxil | 50 mg/kg | Twice a day for 5 days |
Group No. | Virus titer (Mean Log10 PFU ± SD/g) a | |||
---|---|---|---|---|
Day 3 | Day 6 | |||
Nasal Turbinate | Lung | Nasal Turbinate | Lung | |
1 | 5.6 ± 0.3 | 7.2 ± 0.2 | 4.8 ± 0.4 | 5.3 ± 0.3 |
2 | 5.8 ± 0.2 | 6.3 ± 0.1c | 4.4 ± 0.5 | 4.9 ± 0.1 |
3 | 5.5 ± 0.2 | 6.5 ± 0.2 | 4.2 ± 0.5 | 4.8 ± 0.4 |
4 | 3.9 ± 0.7 ** | 6.2 ± 0.2 | 3.9, <1.7, <1.7 * | 4.8 ± 0.7 |
5 | 3.4, <1.7 b, <1.7 ** | 3.5 ± 0.7 ** | 5.1, <1.7, <1.7 | 3.2 ± 0.5 ** |
6 | 2.6, <1.7, <1.7 ** | 3.1, 3.5, <1.7 ** | 2.8, <1.7, <1.7 * | 3.1, 1.8, <1.7 ** |
7 | 3.1 ± 0.3 ** | 3.4 ± 0.7 ** | 2.3, <1.7, <1.7 ** | 3.0, <1.7, <1.7 ** |
8 | 2.5, 2.6, <1.7 ** | <1.7, <1.7, <1.7 ** | 3.0, <1.7, <1.7 * | <1.7, <1.7, <1.7 ** |
9 | 2.6, <1.7, <1.7 ** | <1.7, <1.7, <1.7 ** | <1.7, <1.7, <1.7 ** | <1.7, <1.7, <1.7 ** |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kiso, M.; Yamayoshi, S.; Furusawa, Y.; Imai, M.; Kawaoka, Y. Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil. Viruses 2019, 11, 1066. https://doi.org/10.3390/v11111066
Kiso M, Yamayoshi S, Furusawa Y, Imai M, Kawaoka Y. Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil. Viruses. 2019; 11(11):1066. https://doi.org/10.3390/v11111066
Chicago/Turabian StyleKiso, Maki, Seiya Yamayoshi, Yuri Furusawa, Masaki Imai, and Yoshihiro Kawaoka. 2019. "Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil" Viruses 11, no. 11: 1066. https://doi.org/10.3390/v11111066